Discovery of antitumor anthra[2,3-b]furan-3-carboxamides: Optimization of synthesis and evaluation of antitumor properties

Anthraquinones and their analogues, in particular heteroarene-fused anthracendiones, are prospective scaffolds for new compounds with improved antitumor characteristics. We herein report the use of a ‘scaffold hopping’ approach for the replacement of the core structure in the previously discovered h...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of medicinal chemistry 2016-04, Vol.112, p.114-129
Hauptverfasser: Shchekotikhin, Andrey E., Dezhenkova, Lyubov G., Tsvetkov, Vladimir B., Luzikov, Yuri N., Volodina, Yulia L., Tatarskiy, Victor V., Kalinina, Anastasia A., Treshalin, Michael I., Treshalina, Helen M., Romanenko, Vladimir I., Kaluzhny, Dmitry N., Kubbutat, Michael, Schols, Dominique, Pommier, Yves, Shtil, Alexander A., Preobrazhenskaya, Maria N.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 129
container_issue
container_start_page 114
container_title European journal of medicinal chemistry
container_volume 112
creator Shchekotikhin, Andrey E.
Dezhenkova, Lyubov G.
Tsvetkov, Vladimir B.
Luzikov, Yuri N.
Volodina, Yulia L.
Tatarskiy, Victor V.
Kalinina, Anastasia A.
Treshalin, Michael I.
Treshalina, Helen M.
Romanenko, Vladimir I.
Kaluzhny, Dmitry N.
Kubbutat, Michael
Schols, Dominique
Pommier, Yves
Shtil, Alexander A.
Preobrazhenskaya, Maria N.
description Anthraquinones and their analogues, in particular heteroarene-fused anthracendiones, are prospective scaffolds for new compounds with improved antitumor characteristics. We herein report the use of a ‘scaffold hopping’ approach for the replacement of the core structure in the previously discovered hit compound naphtho[2,3-f]indole-5,10-dione 2 with an alternative anthra[2,3-b]furan-5,10-dione scaffold. Among 13 newly synthesized derivatives the majority of 4,11-dihydroxy-2-methyl-5,10-dioxoanthra[2,3-b]furan-3-carboxamides demonstrated a high antiproliferative potency against a panel of wild type and drug resistant tumor cell lines, a property superior over the reference drug doxorubicin or lead naphtho[2,3-f]indole-5,10-dione 2. At low micromolar concentrations the selected derivative of (R)-3-aminopyrrolidine 3c and its stereoisomer (S)-3-aminopyrrolidine 3d caused an apoptotic cell death preceded by an arrest in the G2/M phase. Studies of intracellular targets showed that 3c and 3d formed stable intercalative complexes with the duplex DNA as determined by spectral analysis and molecular docking. Both 3c and 3d attenuated topoisomerase 1 and 2 mediated unwinding of the supercoiled DNA via a mechanism different from conventional DNA-enzyme tertiary complex formation. Furthermore, 3d decreased the activity of selected human protein kinases in vitro, indicating multiple targeting by the new chemotype. Finally, 3d demonstrated an antitumor activity in a model of murine intraperitoneally transplanted P388 leukemia, achieving the increase of animal life span up to 262% at tolerable doses. Altogether, the ‘scaffold hopping’ demonstrated its productivity for obtaining new perspective antitumor drug candidates. [Display omitted] •A series of novel anthra[2,3-b]furan-3-carboxamides was designed and synthesized.•Some derivatives are highly potent against drug resistant tumor cells.•Anthrafurandiones form stable complexes with double stranded DNA.•Anthrafurandiones inhibit Top1, 2 and protein kinases.•One compound showed a remarkable antitumor potency in vivo.
doi_str_mv 10.1016/j.ejmech.2016.01.050
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7832087</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0223523416300587</els_id><sourcerecordid>1770876672</sourcerecordid><originalsourceid>FETCH-LOGICAL-c463t-586f29e718195bc15c2baeba2cac4ba9a1f00b4b9273ceecbb0cf37f8c7e94023</originalsourceid><addsrcrecordid>eNp9kU9v1DAQxS1ERbeFb4DQHjmQMLaTOOGAVJXyR6rUSzkhZNnOhPUqiYPtrNh-ehxt2dJLT7Y1894bz4-Q1xRyCrR6v81xO6DZ5Cy9cqA5lPCMrKio6oyzsnhOVsAYz0rGi1NyFsIWAMoK4AU5ZVXdAKX1itx9ssG4Hfr92nVrNUYb58H55bbx6gd7xzP9s5u9GjOeGeW1-6MG22L4sL6Zoh3snYrWjYs47JMGgw1J3K5xp_r5WHswnryb0EeL4SU56VQf8NX9eU6-f766vfyaXd98-XZ5cZ2ZouIxK-uqYw0KWtOm1IaWhmmFWjGjTKFVo2gHoAvdMMENotEaTMdFVxuBTQGMn5OPB99p1gO2BsfoVS8nbwfl99IpKx9XRruRv9xOipozqEUyeHtv4N3vGUOUQ1oa9r0a0c1BUiFSW1WJJas4tBrvQvDYHWMoyAWb3MoDNrlgk0BlwpZkb_4f8Sj6x-nhD5gWtbPoZTAWR4Ot9WiibJ19OuEvuKyvrg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1770876672</pqid></control><display><type>article</type><title>Discovery of antitumor anthra[2,3-b]furan-3-carboxamides: Optimization of synthesis and evaluation of antitumor properties</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Shchekotikhin, Andrey E. ; Dezhenkova, Lyubov G. ; Tsvetkov, Vladimir B. ; Luzikov, Yuri N. ; Volodina, Yulia L. ; Tatarskiy, Victor V. ; Kalinina, Anastasia A. ; Treshalin, Michael I. ; Treshalina, Helen M. ; Romanenko, Vladimir I. ; Kaluzhny, Dmitry N. ; Kubbutat, Michael ; Schols, Dominique ; Pommier, Yves ; Shtil, Alexander A. ; Preobrazhenskaya, Maria N.</creator><creatorcontrib>Shchekotikhin, Andrey E. ; Dezhenkova, Lyubov G. ; Tsvetkov, Vladimir B. ; Luzikov, Yuri N. ; Volodina, Yulia L. ; Tatarskiy, Victor V. ; Kalinina, Anastasia A. ; Treshalin, Michael I. ; Treshalina, Helen M. ; Romanenko, Vladimir I. ; Kaluzhny, Dmitry N. ; Kubbutat, Michael ; Schols, Dominique ; Pommier, Yves ; Shtil, Alexander A. ; Preobrazhenskaya, Maria N.</creatorcontrib><description>Anthraquinones and their analogues, in particular heteroarene-fused anthracendiones, are prospective scaffolds for new compounds with improved antitumor characteristics. We herein report the use of a ‘scaffold hopping’ approach for the replacement of the core structure in the previously discovered hit compound naphtho[2,3-f]indole-5,10-dione 2 with an alternative anthra[2,3-b]furan-5,10-dione scaffold. Among 13 newly synthesized derivatives the majority of 4,11-dihydroxy-2-methyl-5,10-dioxoanthra[2,3-b]furan-3-carboxamides demonstrated a high antiproliferative potency against a panel of wild type and drug resistant tumor cell lines, a property superior over the reference drug doxorubicin or lead naphtho[2,3-f]indole-5,10-dione 2. At low micromolar concentrations the selected derivative of (R)-3-aminopyrrolidine 3c and its stereoisomer (S)-3-aminopyrrolidine 3d caused an apoptotic cell death preceded by an arrest in the G2/M phase. Studies of intracellular targets showed that 3c and 3d formed stable intercalative complexes with the duplex DNA as determined by spectral analysis and molecular docking. Both 3c and 3d attenuated topoisomerase 1 and 2 mediated unwinding of the supercoiled DNA via a mechanism different from conventional DNA-enzyme tertiary complex formation. Furthermore, 3d decreased the activity of selected human protein kinases in vitro, indicating multiple targeting by the new chemotype. Finally, 3d demonstrated an antitumor activity in a model of murine intraperitoneally transplanted P388 leukemia, achieving the increase of animal life span up to 262% at tolerable doses. Altogether, the ‘scaffold hopping’ demonstrated its productivity for obtaining new perspective antitumor drug candidates. [Display omitted] •A series of novel anthra[2,3-b]furan-3-carboxamides was designed and synthesized.•Some derivatives are highly potent against drug resistant tumor cells.•Anthrafurandiones form stable complexes with double stranded DNA.•Anthrafurandiones inhibit Top1, 2 and protein kinases.•One compound showed a remarkable antitumor potency in vivo.</description><identifier>ISSN: 0223-5234</identifier><identifier>EISSN: 1768-3254</identifier><identifier>DOI: 10.1016/j.ejmech.2016.01.050</identifier><identifier>PMID: 26890118</identifier><language>eng</language><publisher>France: Elsevier Masson SAS</publisher><subject>Animals ; Anthra[2,3-b]furan-3-carboxamides ; Anthracenes - chemistry ; Anthracenes - pharmacology ; Anthracenes - therapeutic use ; Antineoplastic Agents - chemistry ; Antineoplastic Agents - pharmacology ; Antineoplastic Agents - therapeutic use ; Antitumor activity ; Cell Line, Tumor ; Circumvention of multidrug resistance ; Cytotoxicity ; DNA ligands ; Drug Resistance, Multiple ; Drug Resistance, Neoplasm ; Drug Screening Assays, Antitumor ; Furans - chemistry ; Furans - pharmacology ; Furans - therapeutic use ; Humans ; Leukemia - drug therapy ; Leukemia - metabolism ; Mice ; Neoplasms - drug therapy ; Neoplasms - metabolism ; Protein kinase inhibitors ; Protein Kinase Inhibitors - chemistry ; Protein Kinase Inhibitors - pharmacology ; Protein Kinase Inhibitors - therapeutic use ; Structure-Activity Relationship ; Topoisomerase inhibitors ; Topoisomerase Inhibitors - chemistry ; Topoisomerase Inhibitors - pharmacology ; Topoisomerase Inhibitors - therapeutic use</subject><ispartof>European journal of medicinal chemistry, 2016-04, Vol.112, p.114-129</ispartof><rights>2016 Elsevier Masson SAS</rights><rights>Copyright © 2016 Elsevier Masson SAS. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c463t-586f29e718195bc15c2baeba2cac4ba9a1f00b4b9273ceecbb0cf37f8c7e94023</citedby><cites>FETCH-LOGICAL-c463t-586f29e718195bc15c2baeba2cac4ba9a1f00b4b9273ceecbb0cf37f8c7e94023</cites><orcidid>0000-0002-6912-5579</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0223523416300587$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26890118$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Shchekotikhin, Andrey E.</creatorcontrib><creatorcontrib>Dezhenkova, Lyubov G.</creatorcontrib><creatorcontrib>Tsvetkov, Vladimir B.</creatorcontrib><creatorcontrib>Luzikov, Yuri N.</creatorcontrib><creatorcontrib>Volodina, Yulia L.</creatorcontrib><creatorcontrib>Tatarskiy, Victor V.</creatorcontrib><creatorcontrib>Kalinina, Anastasia A.</creatorcontrib><creatorcontrib>Treshalin, Michael I.</creatorcontrib><creatorcontrib>Treshalina, Helen M.</creatorcontrib><creatorcontrib>Romanenko, Vladimir I.</creatorcontrib><creatorcontrib>Kaluzhny, Dmitry N.</creatorcontrib><creatorcontrib>Kubbutat, Michael</creatorcontrib><creatorcontrib>Schols, Dominique</creatorcontrib><creatorcontrib>Pommier, Yves</creatorcontrib><creatorcontrib>Shtil, Alexander A.</creatorcontrib><creatorcontrib>Preobrazhenskaya, Maria N.</creatorcontrib><title>Discovery of antitumor anthra[2,3-b]furan-3-carboxamides: Optimization of synthesis and evaluation of antitumor properties</title><title>European journal of medicinal chemistry</title><addtitle>Eur J Med Chem</addtitle><description>Anthraquinones and their analogues, in particular heteroarene-fused anthracendiones, are prospective scaffolds for new compounds with improved antitumor characteristics. We herein report the use of a ‘scaffold hopping’ approach for the replacement of the core structure in the previously discovered hit compound naphtho[2,3-f]indole-5,10-dione 2 with an alternative anthra[2,3-b]furan-5,10-dione scaffold. Among 13 newly synthesized derivatives the majority of 4,11-dihydroxy-2-methyl-5,10-dioxoanthra[2,3-b]furan-3-carboxamides demonstrated a high antiproliferative potency against a panel of wild type and drug resistant tumor cell lines, a property superior over the reference drug doxorubicin or lead naphtho[2,3-f]indole-5,10-dione 2. At low micromolar concentrations the selected derivative of (R)-3-aminopyrrolidine 3c and its stereoisomer (S)-3-aminopyrrolidine 3d caused an apoptotic cell death preceded by an arrest in the G2/M phase. Studies of intracellular targets showed that 3c and 3d formed stable intercalative complexes with the duplex DNA as determined by spectral analysis and molecular docking. Both 3c and 3d attenuated topoisomerase 1 and 2 mediated unwinding of the supercoiled DNA via a mechanism different from conventional DNA-enzyme tertiary complex formation. Furthermore, 3d decreased the activity of selected human protein kinases in vitro, indicating multiple targeting by the new chemotype. Finally, 3d demonstrated an antitumor activity in a model of murine intraperitoneally transplanted P388 leukemia, achieving the increase of animal life span up to 262% at tolerable doses. Altogether, the ‘scaffold hopping’ demonstrated its productivity for obtaining new perspective antitumor drug candidates. [Display omitted] •A series of novel anthra[2,3-b]furan-3-carboxamides was designed and synthesized.•Some derivatives are highly potent against drug resistant tumor cells.•Anthrafurandiones form stable complexes with double stranded DNA.•Anthrafurandiones inhibit Top1, 2 and protein kinases.•One compound showed a remarkable antitumor potency in vivo.</description><subject>Animals</subject><subject>Anthra[2,3-b]furan-3-carboxamides</subject><subject>Anthracenes - chemistry</subject><subject>Anthracenes - pharmacology</subject><subject>Anthracenes - therapeutic use</subject><subject>Antineoplastic Agents - chemistry</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Antitumor activity</subject><subject>Cell Line, Tumor</subject><subject>Circumvention of multidrug resistance</subject><subject>Cytotoxicity</subject><subject>DNA ligands</subject><subject>Drug Resistance, Multiple</subject><subject>Drug Resistance, Neoplasm</subject><subject>Drug Screening Assays, Antitumor</subject><subject>Furans - chemistry</subject><subject>Furans - pharmacology</subject><subject>Furans - therapeutic use</subject><subject>Humans</subject><subject>Leukemia - drug therapy</subject><subject>Leukemia - metabolism</subject><subject>Mice</subject><subject>Neoplasms - drug therapy</subject><subject>Neoplasms - metabolism</subject><subject>Protein kinase inhibitors</subject><subject>Protein Kinase Inhibitors - chemistry</subject><subject>Protein Kinase Inhibitors - pharmacology</subject><subject>Protein Kinase Inhibitors - therapeutic use</subject><subject>Structure-Activity Relationship</subject><subject>Topoisomerase inhibitors</subject><subject>Topoisomerase Inhibitors - chemistry</subject><subject>Topoisomerase Inhibitors - pharmacology</subject><subject>Topoisomerase Inhibitors - therapeutic use</subject><issn>0223-5234</issn><issn>1768-3254</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU9v1DAQxS1ERbeFb4DQHjmQMLaTOOGAVJXyR6rUSzkhZNnOhPUqiYPtrNh-ehxt2dJLT7Y1894bz4-Q1xRyCrR6v81xO6DZ5Cy9cqA5lPCMrKio6oyzsnhOVsAYz0rGi1NyFsIWAMoK4AU5ZVXdAKX1itx9ssG4Hfr92nVrNUYb58H55bbx6gd7xzP9s5u9GjOeGeW1-6MG22L4sL6Zoh3snYrWjYs47JMGgw1J3K5xp_r5WHswnryb0EeL4SU56VQf8NX9eU6-f766vfyaXd98-XZ5cZ2ZouIxK-uqYw0KWtOm1IaWhmmFWjGjTKFVo2gHoAvdMMENotEaTMdFVxuBTQGMn5OPB99p1gO2BsfoVS8nbwfl99IpKx9XRruRv9xOipozqEUyeHtv4N3vGUOUQ1oa9r0a0c1BUiFSW1WJJas4tBrvQvDYHWMoyAWb3MoDNrlgk0BlwpZkb_4f8Sj6x-nhD5gWtbPoZTAWR4Ot9WiibJ19OuEvuKyvrg</recordid><startdate>20160413</startdate><enddate>20160413</enddate><creator>Shchekotikhin, Andrey E.</creator><creator>Dezhenkova, Lyubov G.</creator><creator>Tsvetkov, Vladimir B.</creator><creator>Luzikov, Yuri N.</creator><creator>Volodina, Yulia L.</creator><creator>Tatarskiy, Victor V.</creator><creator>Kalinina, Anastasia A.</creator><creator>Treshalin, Michael I.</creator><creator>Treshalina, Helen M.</creator><creator>Romanenko, Vladimir I.</creator><creator>Kaluzhny, Dmitry N.</creator><creator>Kubbutat, Michael</creator><creator>Schols, Dominique</creator><creator>Pommier, Yves</creator><creator>Shtil, Alexander A.</creator><creator>Preobrazhenskaya, Maria N.</creator><general>Elsevier Masson SAS</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-6912-5579</orcidid></search><sort><creationdate>20160413</creationdate><title>Discovery of antitumor anthra[2,3-b]furan-3-carboxamides: Optimization of synthesis and evaluation of antitumor properties</title><author>Shchekotikhin, Andrey E. ; Dezhenkova, Lyubov G. ; Tsvetkov, Vladimir B. ; Luzikov, Yuri N. ; Volodina, Yulia L. ; Tatarskiy, Victor V. ; Kalinina, Anastasia A. ; Treshalin, Michael I. ; Treshalina, Helen M. ; Romanenko, Vladimir I. ; Kaluzhny, Dmitry N. ; Kubbutat, Michael ; Schols, Dominique ; Pommier, Yves ; Shtil, Alexander A. ; Preobrazhenskaya, Maria N.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c463t-586f29e718195bc15c2baeba2cac4ba9a1f00b4b9273ceecbb0cf37f8c7e94023</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Animals</topic><topic>Anthra[2,3-b]furan-3-carboxamides</topic><topic>Anthracenes - chemistry</topic><topic>Anthracenes - pharmacology</topic><topic>Anthracenes - therapeutic use</topic><topic>Antineoplastic Agents - chemistry</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Antitumor activity</topic><topic>Cell Line, Tumor</topic><topic>Circumvention of multidrug resistance</topic><topic>Cytotoxicity</topic><topic>DNA ligands</topic><topic>Drug Resistance, Multiple</topic><topic>Drug Resistance, Neoplasm</topic><topic>Drug Screening Assays, Antitumor</topic><topic>Furans - chemistry</topic><topic>Furans - pharmacology</topic><topic>Furans - therapeutic use</topic><topic>Humans</topic><topic>Leukemia - drug therapy</topic><topic>Leukemia - metabolism</topic><topic>Mice</topic><topic>Neoplasms - drug therapy</topic><topic>Neoplasms - metabolism</topic><topic>Protein kinase inhibitors</topic><topic>Protein Kinase Inhibitors - chemistry</topic><topic>Protein Kinase Inhibitors - pharmacology</topic><topic>Protein Kinase Inhibitors - therapeutic use</topic><topic>Structure-Activity Relationship</topic><topic>Topoisomerase inhibitors</topic><topic>Topoisomerase Inhibitors - chemistry</topic><topic>Topoisomerase Inhibitors - pharmacology</topic><topic>Topoisomerase Inhibitors - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shchekotikhin, Andrey E.</creatorcontrib><creatorcontrib>Dezhenkova, Lyubov G.</creatorcontrib><creatorcontrib>Tsvetkov, Vladimir B.</creatorcontrib><creatorcontrib>Luzikov, Yuri N.</creatorcontrib><creatorcontrib>Volodina, Yulia L.</creatorcontrib><creatorcontrib>Tatarskiy, Victor V.</creatorcontrib><creatorcontrib>Kalinina, Anastasia A.</creatorcontrib><creatorcontrib>Treshalin, Michael I.</creatorcontrib><creatorcontrib>Treshalina, Helen M.</creatorcontrib><creatorcontrib>Romanenko, Vladimir I.</creatorcontrib><creatorcontrib>Kaluzhny, Dmitry N.</creatorcontrib><creatorcontrib>Kubbutat, Michael</creatorcontrib><creatorcontrib>Schols, Dominique</creatorcontrib><creatorcontrib>Pommier, Yves</creatorcontrib><creatorcontrib>Shtil, Alexander A.</creatorcontrib><creatorcontrib>Preobrazhenskaya, Maria N.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>European journal of medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shchekotikhin, Andrey E.</au><au>Dezhenkova, Lyubov G.</au><au>Tsvetkov, Vladimir B.</au><au>Luzikov, Yuri N.</au><au>Volodina, Yulia L.</au><au>Tatarskiy, Victor V.</au><au>Kalinina, Anastasia A.</au><au>Treshalin, Michael I.</au><au>Treshalina, Helen M.</au><au>Romanenko, Vladimir I.</au><au>Kaluzhny, Dmitry N.</au><au>Kubbutat, Michael</au><au>Schols, Dominique</au><au>Pommier, Yves</au><au>Shtil, Alexander A.</au><au>Preobrazhenskaya, Maria N.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Discovery of antitumor anthra[2,3-b]furan-3-carboxamides: Optimization of synthesis and evaluation of antitumor properties</atitle><jtitle>European journal of medicinal chemistry</jtitle><addtitle>Eur J Med Chem</addtitle><date>2016-04-13</date><risdate>2016</risdate><volume>112</volume><spage>114</spage><epage>129</epage><pages>114-129</pages><issn>0223-5234</issn><eissn>1768-3254</eissn><abstract>Anthraquinones and their analogues, in particular heteroarene-fused anthracendiones, are prospective scaffolds for new compounds with improved antitumor characteristics. We herein report the use of a ‘scaffold hopping’ approach for the replacement of the core structure in the previously discovered hit compound naphtho[2,3-f]indole-5,10-dione 2 with an alternative anthra[2,3-b]furan-5,10-dione scaffold. Among 13 newly synthesized derivatives the majority of 4,11-dihydroxy-2-methyl-5,10-dioxoanthra[2,3-b]furan-3-carboxamides demonstrated a high antiproliferative potency against a panel of wild type and drug resistant tumor cell lines, a property superior over the reference drug doxorubicin or lead naphtho[2,3-f]indole-5,10-dione 2. At low micromolar concentrations the selected derivative of (R)-3-aminopyrrolidine 3c and its stereoisomer (S)-3-aminopyrrolidine 3d caused an apoptotic cell death preceded by an arrest in the G2/M phase. Studies of intracellular targets showed that 3c and 3d formed stable intercalative complexes with the duplex DNA as determined by spectral analysis and molecular docking. Both 3c and 3d attenuated topoisomerase 1 and 2 mediated unwinding of the supercoiled DNA via a mechanism different from conventional DNA-enzyme tertiary complex formation. Furthermore, 3d decreased the activity of selected human protein kinases in vitro, indicating multiple targeting by the new chemotype. Finally, 3d demonstrated an antitumor activity in a model of murine intraperitoneally transplanted P388 leukemia, achieving the increase of animal life span up to 262% at tolerable doses. Altogether, the ‘scaffold hopping’ demonstrated its productivity for obtaining new perspective antitumor drug candidates. [Display omitted] •A series of novel anthra[2,3-b]furan-3-carboxamides was designed and synthesized.•Some derivatives are highly potent against drug resistant tumor cells.•Anthrafurandiones form stable complexes with double stranded DNA.•Anthrafurandiones inhibit Top1, 2 and protein kinases.•One compound showed a remarkable antitumor potency in vivo.</abstract><cop>France</cop><pub>Elsevier Masson SAS</pub><pmid>26890118</pmid><doi>10.1016/j.ejmech.2016.01.050</doi><tpages>16</tpages><orcidid>https://orcid.org/0000-0002-6912-5579</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0223-5234
ispartof European journal of medicinal chemistry, 2016-04, Vol.112, p.114-129
issn 0223-5234
1768-3254
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7832087
source MEDLINE; Elsevier ScienceDirect Journals
subjects Animals
Anthra[2,3-b]furan-3-carboxamides
Anthracenes - chemistry
Anthracenes - pharmacology
Anthracenes - therapeutic use
Antineoplastic Agents - chemistry
Antineoplastic Agents - pharmacology
Antineoplastic Agents - therapeutic use
Antitumor activity
Cell Line, Tumor
Circumvention of multidrug resistance
Cytotoxicity
DNA ligands
Drug Resistance, Multiple
Drug Resistance, Neoplasm
Drug Screening Assays, Antitumor
Furans - chemistry
Furans - pharmacology
Furans - therapeutic use
Humans
Leukemia - drug therapy
Leukemia - metabolism
Mice
Neoplasms - drug therapy
Neoplasms - metabolism
Protein kinase inhibitors
Protein Kinase Inhibitors - chemistry
Protein Kinase Inhibitors - pharmacology
Protein Kinase Inhibitors - therapeutic use
Structure-Activity Relationship
Topoisomerase inhibitors
Topoisomerase Inhibitors - chemistry
Topoisomerase Inhibitors - pharmacology
Topoisomerase Inhibitors - therapeutic use
title Discovery of antitumor anthra[2,3-b]furan-3-carboxamides: Optimization of synthesis and evaluation of antitumor properties
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T14%3A47%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Discovery%20of%20antitumor%20anthra%5B2,3-b%5Dfuran-3-carboxamides:%20Optimization%20of%20synthesis%20and%20evaluation%20of%20antitumor%20properties&rft.jtitle=European%20journal%20of%20medicinal%20chemistry&rft.au=Shchekotikhin,%20Andrey%20E.&rft.date=2016-04-13&rft.volume=112&rft.spage=114&rft.epage=129&rft.pages=114-129&rft.issn=0223-5234&rft.eissn=1768-3254&rft_id=info:doi/10.1016/j.ejmech.2016.01.050&rft_dat=%3Cproquest_pubme%3E1770876672%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1770876672&rft_id=info:pmid/26890118&rft_els_id=S0223523416300587&rfr_iscdi=true